Related Experiment Video
Updated: Feb 1, 2026

In vivo Imaging Method to Distinguish Acute and Chronic Inflammation
Published on: August 16, 2013
Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias
Shahzya Chaudhury1,2, Caitríona O'Connor1, Ana Cañete1
1Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Insights
Acute myeloid leukaemia (AML) in children is often fatal, with relapse being a common cause of death. This study reveals that the age of the cell of origin significantly impacts AML development and characteristics, offering new therapeutic targets.
Area of Science:
- Hematology
- Pediatric Oncology
- Cancer Biology
Background:
- Acute myeloid leukaemia (AML) is a significant cause of cancer-related death in children.
- Relapse is the primary cause of mortality in pediatric AML patients.
- Understanding the biological differences in AML based on cell origin is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the role of cell-of-origin age in the development and characteristics of Acute Myeloid Leukaemia (AML).
- To identify distinct biological pathways and prognostic markers in pediatric AML.
- To establish in vivo murine models for studying pediatric AML and developing novel therapeutic strategies.
Main Methods:
- In vivo modeling of AML in mice.
- Transcriptional analysis of leukaemic cells.
- Analysis of human pediatric AML patient samples.
Main Results:
- AML development is discriminated by the age of the cell of origin: young cells can lead to myeloid, lymphoid, or mixed acute leukaemias, while adult cells exclusively produce AML with shorter latency.
- Young AML cells do not remodel the bone marrow stroma, unlike adult AML cells.
- Transcriptional analysis revealed upregulation of immune pathways in young AML, with human pediatric samples showing a similar immune cell interaction gene signature, highlighting RGS10 and FAM26F as prognostically significant.
Conclusions:
- The age of the cell of origin is a critical factor in determining AML phenotype, latency, and stromal interaction.
- Immune pathway dysregulation is a key feature of pediatric AML.
- RGS10 and FAM26F are identified as potential prognostic markers for pediatric AML, paving the way for developing pediatric-specific therapeutic strategies.
Abstract:
Acute myeloid leukaemia (AML) affects children and adults of all ages. AML remains one of the major causes of death in children with cancer and for children with AML relapse is the most common cause of death. Here, by modelling AML in vivo we demonstrate that AML is discriminated by the age of the cell of origin. Young cells give rise to myeloid, lymphoid or mixed phenotype acute leukaemia, whereas adult cells give rise exclusively to AML, with a shorter latency. Unlike adult, young AML cells do not remodel the bone marrow stroma. Transcriptional analysis distinguishes young AML by the upregulation of immune pathways. Analysis of human paediatric AML samples recapitulates a paediatric immune cell interaction gene signature, highlighting two genes, RGS10 and FAM26F as prognostically significant. This work advances our understanding of paediatric AML biology, and provides murine models that offer the potential for developing paediatric specific therapeutic strategies.
Related Concept Videos
Molecular Models
Aging
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
What is Conservation Biology?
Molecular Orbital Theory I
Biological Effects of Radiation
The Effect of Aging on Tissues

